Share 'Sarepta Therapeutics shares jump on news of critic’s departure from FDA'
"Arguably the most oppositional team leader of the review board to the approval of Duchenne Muscular Dystrophy (DMD)-treating pipeline drug eteplirsen, has officially left the FDA."
You can share this discussion in two ways…
Share this link:
Send it with your computer's email program: Email this